Phase 2 cagrilintide alone ~10.8% body weight reduction at 26 weeks (4.5mg) Phase 2 CagriSema combo ~15.6% body weight reduction at 32 weeks Phase 3 REDEFINE 1 ~22.7% body weight reduction at 68 weeks Phase 2 CagriSema combination trial The Phase 2 trial of CagriSema was published in The Lancet in 2023, and its results attracted immediate attention
Influence of maternal MTHFR A1298C polymorphism on the risk in offspring of schizophrenia
Patients in their 30s, 40s, and 50s who have maintained training intensity but notice slower recovery, reduced lean mass, and more difficult fat loss are the population that responds most predictably to GH secretagogue therapy
It replaced the temporary use of 90471 during the public health emergency
The clearest role for Put-GABA has been shown in fear extinction memory, where distinct but complementary inhibitory functions of striatal DA/Put-GABA co-release onto intercalated cells has been described (Wu et al., 2019)
How does Dihexa work in the brain
